B. Dizier

A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies.

Lihui Zhao, L. Tian, Lee-Jen Wei, 2016, Biometrics.

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

Bart Spiessens, Benjamin Dizier, Stefan Suciu, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Th1/IFNg Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

J. Goeman, H. V. Houwelingen, J. Kirkwood, 2020 .

A Th1/IFN g Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non – Small Cell Lung Cancer A

J. Goeman, H. V. Houwelingen, J. Kirkwood, 2020 .

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

A. Hauschild, S. Puig, J. Goeman, 2018, The Lancet. Oncology.

Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study

S. Garcet, B. Dizier, D. Baeten, 2021, The British journal of dermatology.

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

J. Goeman, H. V. van Houwelingen, J. Kirkwood, 2019, Clinical Cancer Research.

Abstract A37: Identification of a gene expression signature predictive of clinical activity following MAGE‐A3 ASCI treatment

J. Vansteenkiste, B. Dizier, Fernando Ulloa-Montoya, 2009 .

Testing interaction between treatment and high‐dimensional covariates in randomized clinical trials

Andrea Callegaro, Bart Spiessens, Benjamin Dizier, 2017, Biometrical journal. Biometrische Zeitschrift.